Abstract
As an MHC class I protein, the disease association of HLA-B27 with inflammatory arthritis has been widely assumed to imply a role for the T cell antigen receptor (TCR) in disease. However, in addition to their classical antigen-presenting role, HLA class I proteins are recognised by members of the killer immunoglobulin receptor (KIR) and leukocyte immunoglobulin-like receptor (LILR / ILT / LIR) families. Unusual properties of HLA-B27 include an ability of free heavy chains (FHC) to reach the cell surface in the absence of β2m and to maintain their peptide-binding groove in vitro. This review describes immunomodulatory receptors that recognise HLA class I, and the recognition of HLA-B27 in both the classical β2m-associated and β2m-independent forms by members of the KIR and LILR families. Alternative recognition of different forms of HLA-B27 by leukocyte receptors could influence the function of cells from both innate and adaptive immune systems, and may indicate a role for various leukocyte populations in HLA-B27-associated inflammatory disease.
Keywords: hla-b27, spondyloarthropathy, ankylosing spondylitis, heavy chain, hc-b27, tcr
Current Molecular Medicine
Title: Recognition of Classical and Heavy Chain Forms of HLA-B27 by Leukocyte Receptors
Volume: 4 Issue: 1
Author(s): Rachel L. Allen and John Trowsdale
Affiliation:
Keywords: hla-b27, spondyloarthropathy, ankylosing spondylitis, heavy chain, hc-b27, tcr
Abstract: As an MHC class I protein, the disease association of HLA-B27 with inflammatory arthritis has been widely assumed to imply a role for the T cell antigen receptor (TCR) in disease. However, in addition to their classical antigen-presenting role, HLA class I proteins are recognised by members of the killer immunoglobulin receptor (KIR) and leukocyte immunoglobulin-like receptor (LILR / ILT / LIR) families. Unusual properties of HLA-B27 include an ability of free heavy chains (FHC) to reach the cell surface in the absence of β2m and to maintain their peptide-binding groove in vitro. This review describes immunomodulatory receptors that recognise HLA class I, and the recognition of HLA-B27 in both the classical β2m-associated and β2m-independent forms by members of the KIR and LILR families. Alternative recognition of different forms of HLA-B27 by leukocyte receptors could influence the function of cells from both innate and adaptive immune systems, and may indicate a role for various leukocyte populations in HLA-B27-associated inflammatory disease.
Export Options
About this article
Cite this article as:
Allen L. Rachel and Trowsdale John, Recognition of Classical and Heavy Chain Forms of HLA-B27 by Leukocyte Receptors, Current Molecular Medicine 2004; 4 (1) . https://dx.doi.org/10.2174/1566524043479329
DOI https://dx.doi.org/10.2174/1566524043479329 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Application of 3D Biomimetic Models in Drug Delivery and Regenerative Medicine
Current Pharmaceutical Design Update on Anti-TNF-Alpha Treatment in Rheumatic Diseases
Current Drug Therapy Cardiac and Pulmonary Manifestations in the Antiphospholipid Syndrome
Current Rheumatology Reviews TAP-Independent MHC Class I Presentation
Current Immunology Reviews (Discontinued) Susceptibility Genes in Hypertension
Current Pharmaceutical Design Systematic Review of the Role of Microparticles in Systemic Sclerosis
Current Rheumatology Reviews Mechanisms of Drug Hypersensitivity Reactions and the Skin
Recent Patents on Inflammation & Allergy Drug Discovery Familial Mediterranean Fever
Current Rheumatology Reviews Amyloidosis and Auto-Inflammatory Syndromes
Current Drug Targets - Inflammation & Allergy Extracellular Matrix on the Phenotypic Switching of Vascular Smooth Muscle Cells
Current Angiogenesis (Discontinued) Beneficial Role of Vitexin and Isovitexin Flavonoids in the Vascular Endothelium and Cardiovascular System
Current Nutraceuticals New Perspectives in the Pharmacological Potential of Naringin in Medicine
Current Medicinal Chemistry Utilizing Delta Opioid Receptors and Peptides for Cytoprotection: Implications in Stroke and Other Neurological Disorders
CNS & Neurological Disorders - Drug Targets Genetic and Epigenetic Biomarkers for Diagnosis, Prognosis and Treatment of Metabolic Syndrome
Current Pharmaceutical Design Adult Stem Cells and the Clinical Arena: Are we Able to Widely Use this Therapy in Patients with Chronic Limbs Arteriopathy and Ischemic Ulcers without Possibility of Revascularization?
Cardiovascular & Hematological Agents in Medicinal Chemistry Management of Connective Tissue Interstitial Lung Disease
Current Respiratory Medicine Reviews The Triad: Erectile Dysfunction - Endothelial Dysfunction - Cardiovascular Disease
Current Pharmaceutical Design Diabetes and Vascular Disease: Basic Concepts of Nitric Oxide Physiology, Endothelial Dysfunction, Oxidative Stress and Therapeutic Possibilities
Current Vascular Pharmacology Rituximab Therapy and Autoimmune Disease
Current Immunology Reviews (Discontinued) Anti-Inflammatory Effects of Triterpenoids; Naturally Occurring and Synthetic Agents
Mini-Reviews in Organic Chemistry